Cenobamate is under clinical development by SK Life Science and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Cenobamate’s likelihood of approval (LoA) and phase transition for Tonic-Clonic (Grand Mal) Seizure took place on 26 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cenobamate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Cenobamate overview

Cenobamate (Xcopri/ Ontozry) is an anti-epileptic agent. It is formulated as tablets and film coated tablets for oral route of administration. Xcopri is indicated to treat partial-onset seizures in adults 18 years of age and older and hepatic impairment. Ontozry is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Cenobamate (YKP-3089) is under development for the treatment of partial seizures and tonic-clonic seizures. It is a next-generation carbamate. The drug candidate is administered through the oral route in the form of the capsule and tablets. It acts as an anxiolytic well as an anti-epileptic drug compound. The drug candidate is a sodium channel blocke and positive allosteric GABAA modulator. It was also under development for the treatment of anxiety, neuropathic pain and bipolar disorders

SK Life Science overview

SK Life Science (SK Life) a subsidiary of SK Biopharmaceuticals Co Ltd is a developer of medicinal products. The company develops technologies in the areas of biology and discovery, medicinal chemistry and pharmacology. Its biology and discovery research provide lead compound discovery and optimization that indentifies and validates signal and molecular targets. SK Life develops drugs for epilepsy, sleep disorder, neuropathic pain, Alzheimer’s dementia, anxiety, depression, and schizophrenia. The company’s technical expertise includes continuous flow process and chiral chemistry. It develops drugs through partnerships with universities, government organizations, pharmaceutical and biotech companies. SK Life is headquartered in Fair Lawn, New Jersey, the US.

Quick View Cenobamate LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Cenobamate
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.